NOTCH3 and meningioma: This metabolic profile protects cells from ferroptosis and may be a mechanism to both enhance malignancy and resistance to therapeutic interventions such as sorafenib or cisplatin, portending a poor prognosis in NOTCH3-expressing meningiomas.